West Pharmaceutical Services, Inc.
WST
$251.38
$0.130.05%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.07B | 3.02B | 2.96B | 2.90B | 2.89B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.07B | 3.02B | 2.96B | 2.90B | 2.89B |
| Cost of Revenue | 1.97B | 1.94B | 1.92B | 1.90B | 1.89B |
| Gross Profit | 1.10B | 1.07B | 1.04B | 1.00B | 998.50M |
| SG&A Expenses | 389.70M | 365.50M | 346.30M | 334.80M | 334.90M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 1.30M | 900.00K | 1.20M | 900.00K | 900.00K |
| Total Operating Expenses | 2.44B | 2.38B | 2.33B | 2.30B | 2.30B |
| Operating Income | 638.70M | 636.30M | 627.20M | 596.70M | 593.60M |
| Income Before Tax | 615.30M | 616.80M | 611.20M | 582.40M | 600.20M |
| Income Tax Expenses | 121.60M | 125.10M | 123.50M | 115.20M | 107.50M |
| Earnings from Continuing Operations | 493.70 | 491.70 | 487.70 | 467.20 | 492.70 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 493.70M | 491.70M | 487.70M | 467.20M | 492.70M |
| EBIT | 638.70M | 636.30M | 627.20M | 596.70M | 593.60M |
| EBITDA | 810.10M | 801.40M | 789.50M | 756.50M | 749.00M |
| EPS Basic | 6.83 | 6.79 | 6.72 | 6.42 | 6.75 |
| Normalized Basic EPS | 5.72 | 5.68 | 5.58 | 5.29 | 5.27 |
| EPS Diluted | 6.79 | 6.75 | 6.68 | 6.37 | 6.69 |
| Normalized Diluted EPS | 5.69 | 5.64 | 5.54 | 5.25 | 5.22 |
| Average Basic Shares Outstanding | 289.20M | 289.60M | 290.20M | 291.00M | 292.00M |
| Average Diluted Shares Outstanding | 290.80M | 291.40M | 292.20M | 293.40M | 294.70M |
| Dividend Per Share | 0.85 | 0.84 | 0.83 | 0.82 | 0.81 |
| Payout Ratio | 12.40% | 12.34% | 12.32% | 12.76% | 12.00% |